BCL2L1 and cancer: Targeting this mechanism and switching the splicing of BCL-X gene toward the production of the proapoptotic variant thereby offer the opportunity to revert cancer cells resistance to chemotherapeutic drugs and to promote tumor cell death [111, 112].